Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

Nature Clinical Practice Oncology

Volumn 1, Issue 2, 2004, Pages 80-87

  Sartor, Carolyn I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Disease mechanism; EGFR; EGFR inhibitor; Radiosensitizer; Radiotherapy

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CETUXIMAB; DNA DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GW 572106; LAPATINIB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER STAGING; CELL CYCLE PHASE; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DNA REPAIR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 20444492764     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0048     Document Type: Review

References (54)

1. Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: 32S-40S
2. Mendelsohn J and Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799
3. Bonner J et al. (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract]. J Clin Oncol 22: a5507
4. Miyaguchi M et al. (1998) Correlation of epidermal growth factor receptor and radiosensitivity in human maxillary carcinoma cell lines. Acta Otolaryngol (Stockh) 118: 428-431
5. Sheridan MT et al. (1997) Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 5: 180-186
6. Akimoto T et al. (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890
7. Miles L et al. (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiation Oncology Biol Phys 58: 966-971
8. Harari PM and Huang SM (2001) Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49: 427-433
9. Milas L et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708
10. Bonner JA et al. (2000) Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18: 47S-53S
11. Huang SM et al. (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940
12. Nasu S et al. (2001) C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51: 474-477
13. Huang SM et al. (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306
14. Shintani S et al. (2003) Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107: 1030-1037
15. Robert F et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234-3243
16. Bonner J et al. (2000) Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies [abstract]. In American Society of Clinical Oncology 36th Annual Meeting; 2000 May 20-23; New Orleans, LA
17. Withers HR et al. (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27: 131-146
18. Dorr W (1997) Three A's of repopulation during fractionated irradiation of squamous epithelia: asymmetry loss, acceleration of stem-cell divisions and abortive divisions. Int J Radiat Biol 72: 635-643
19. Schmidt-Ullrich RK et al. (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15: 1191-1197
20. Dent P et al. (1999) Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506
21. Milas L et al. (2002) Role of Epidermal Growth Factor Receptor (EGFR) and its Inhibition in Radiotherapy. (Eds Nieder C et al.) Heidelberg: Springer
22. Eriksen JG et al. (2004) The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58: 561-566
23. Mendelsohn J (1997) Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703-2707
24. Rusnak DW et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94
25. Crombet-Ramos T et al. (2002) Anti proliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 101: 567-575
26. Nyati MK et al. (2004) Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 10: 691-700
27. Raben D et al. (2001) in Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications [abstract A756] Clin Cancer Res
28. Solomon B et al. (2003) EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 55: 713-723
29. Buchsbaum DJ et al. (2002) Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 54: 1180-1193
30. Albanell J et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
31. Iliakis G et al. (2003) DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22: 5834-5847
32. Raben D et al. (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29: 37-46
33. Balaban N et al. (1996) The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1314: 147-156
34. Bianco C et al. (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8: 3250-3258
35. Murakami M et al. (2004) Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells. Biochem Biophys Res Commun 319: 114-119
36. Garcia-Barros M et al. (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159
37. Gorski DH et al. (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378
38. Goldman CK et al. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133
39. Huang SM and Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166-2174
40. Hirata A et al. (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560
41. Viloria-Petit A et al. (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Research 61: 5090-5101
42. Hirata A et al. (2004) Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci 95: 614-618
43. Khanna KK and Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254
44. Lieber MR et al. (1997) Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Curr Opin Genet Dev 7: 99-104
45. Bandyopadhyay D et al. (1998) Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568-1573
46. Olayioye MA et al. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167
47. Dent P et al. (2003) MAPK pathways in radiation responses. Oncogene 22: 5885-5896
48. Pirollo KF et al. (1997) Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells. Biochem Biophys Res Commun 230: 196-201
49. Zhou H et al. (2004) Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58: 344-352
50. Brognard J et al. (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997
51. Gupta AK et al. (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892
52. Grana TM et al. (2002) Ras mediates radioresistance through both phosphatidylinositol 3-kinase- dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62: 4142-4150
53. Grana TM et al. (2003) Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res 63: 7807-7814
54. Sarkaria JN et al. (1998) Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58: 4375-4382